Panbela Therapeutics, Inc. (PBLA)
Develops cancer drugs targeting pancreatic cancer and other tumors through experimental polyamine inhibitor treatments.
$0.01+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-93.5%
The outlook
PBLA is trading near its 52-week low, though it sits above both its 50- and 200-day moving averages. Analyst coverage appears thin or unavailable. The stock's neutral score reflects mixed signals between its technical position and broader sentiment.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
$53,888
52-wk high
$2.50
52-wk low
$0.00
50-day avg
$0.01
200-day avg
$0.01
Trailing P/E
—